VALION BIO INC
VBIONASDAQTrading Snapshot
- Day Range
- $2.78 – $2.82
- 52-Week Range
- $2.05 – $32.50
- Volume
- $2.73B
- Avg Volume
- $2.43B
- Shares Outstanding
- 4.2M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $429,502
- Last Q Revenue
- $108,212
- P/E Ratio
- —
- P/S Ratio
- 5.6x
- EPS (TTM)
- $-8.23
- Dividend Yield
- —
- Dilution (1yr)
- −100.0%
Why Investors Own VBIO
- ✓High-growth profile — revenue up +27.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VALION BIO INC
VBIO
StockOtter · stockotter.spaceAbout VALION BIO INC
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2026 / Valion Bio, In
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company) announced today that it
Valion Bio Announces Changes to Management and Board of Directors
Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.
Valion Bio Announces Reverse Stock Split
SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement Formal review accepted July 22 • Ministry begins technical
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early Fall Study drug delivered • IACUC approval secured • Safety study planned to start this week Ne